Briacell Therapeutics Corp. Common Shares (BCTX) Stock Price
BCTXStock
$3.77−49.26%52W
Market Cap$32.80M
P/E—
PEG Ratio—
Div yield—
Beta1.42
BCTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-22.81%
Price vs S&P 500 (4W)-7.42%
VGM Score38.00
BCTX Earnings Surprise History
Q3 24-33.00est. -12.00
Q4 24-23.30est. -19.40
Q1 25-16.40est. -17.60
Q2 250.04est. -12.11
BCTX Analyst Recommendations
Oct 2022
Nov 2022
Dec 2022
Jan 2023
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCTXBriacell Therapeutics Corp. Common Shares | — | — | D | $3.77 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Briacell Therapeutics Corp. Common Shares
BriaCell Therapeutics is a clinical-stage biotech company developing targeted cell-based immunotherapies for cancer. Lead program Bria-IMT is in end-stage clinical trials for breast cancer, while Bria-OTS offers personalized immunotherapy options for breast and prostate cancer. The company is evaluating combination therapy approaches through clinical collaborations.